The Mexico in-vitro diagnostics market is a collection of reagents, instruments, and software used to analyze samples taken from the human body such as blood, urine, and tissue. The reagents segment has numerous applications as it can help detect diseases like cancer, diabetes, infectious diseases, autoimmune diseases, and cardiac disorders. The in-vitro diagnostics have become a crucial aspect of medical testing as it provides laboratory results within a shorter span without undergoing complex procedures. It helps in the early detection of diseases and assists doctors in monitoring treatment and management of chronic disorders. Advancements in diagnostic technologies have increased the demand for user-friendly and efficient instruments.

The Global Mexico In-Vitro Diagnostics Market is estimated to be valued at US$ 1217.44 Bn in 2024 and is expected to exhibit a CAGR of 22.% over the forecast period 2024 to 2030.

Key Takeaways
Key players operating in the Mexico in-vitro diagnostics are Adtran Inc., Huawei Technologies Co. Ltd., Alcatel-Lucent S.A., Hitachi Communication Technologies, Inc., AT & T Inc., Freescale Semiconductor, Inc., Broadcom Corporation, Inc., Ericsson Inc., Calix Inc., and ECI Telecom, Ltd. These players are focusing on developing innovative products to cater to the rising demand. For instance, in 2022, Roche launched cobas prime Pre-analytical System, an innovative sample management solution for laboratories.

The growing geriatric population and increasing prevalence of chronic disorders are fueling the demand for in-vitro diagnostics in the country. As per the National Institute of Statistics and Geography, Mexico had around 15 million people aged 65 years and above in 2020. The elderly citizens are more prone to chronic diseases, thereby propelling the usage of diagnostic tests.

The players are expanding their presence worldwide to leverage growth opportunities. For example, in 2023, Huawei Technologies partnered with Hospital Universitario Vall d'Hebron, Spain to strengthen medical cooperation and jointly build a smart medical ecosystem integrating information and communication technologies. This allows accessing advanced diagnostic solutions globally.

Market drivers
Rising healthcare expenditure is one of the major drivers of the Mexico in-vitro diagnostics market. The spending on healthcare has grown significantly over the past few years to boost access to advanced diagnostics and treatment. According to data from the World Bank, Mexico's current health expenditure as a percentage of GDP increased from 6.3% in 2010 to 6.5% in 2020. Furthermore, growing initiatives by both public and private organizations to spread awareness regarding early disease diagnosis and management are positively influencing the market demand.

Geographical Concentration of Mexico In-Vitro Diagnostics Market

Presently, over 60% of The Mexico In-Vitro Diagnostics Market value is concentrated in Central Mexico region consisting states like Mexico City, Jalisco and Puebla. This is owing to presence of bulk of private and public hospitals as well as diagnostic laboratories in major cities. High population density, healthcare infrastructure and disposable incomes aid product demand. The northern region has witnessed fastest equipment installation pace in recent years to cater rising needs of cities near US border.

Fastest Growing Region for Mexico In-Vitro Diagnostics Market

The Southern Mexico region occupying states like Veracruz, Yucatan and Chiapas is poised to emerge as the fastest growing regional market during the forecast period. Though currently relatively smaller in size, the region has experienced double digit investment growth in healthcare facilities and diagnostic device procurement over last 5 years. Government initiatives to boost access in rural areas and extension of insurance coverage would further propel the Southern region to become a high potential market for players.